EIF2AK3 and neurodegenerative disease: For example, genetic reduction and pharmacological inhibition of the eIF2α kinase PERK (Moreno et al., 2013; Radford et al., 2015; Scheper and Hoozemans, 2015), overexpression of the eIF2α phosphatase GADD34 (Moreno et al., 2012), or promoting its interaction with eif2B (Halliday et al., 2015) has been shown to be effective in mouse models for different neurodegenerative diseases including tauopathies.